108 Received usual care as allocated 92 Followed up at posttreatment 93 Followed up at posttreatment 89 Followed up at 6 months 91 Followed up at 6 months 90 Followed up at 12 months 86 Followed up at 12 months FIGURE 1. Flow chart of participants in the randomized controlled trial. ACR indicates American College of Rheumatology; FM, fibromyalgia.
Objective: To determine the effectiveness of adding psychoeducational treatment implemented in general practice to usual care for patients with fibromyalgia (FM), and to analyze the cost-utility of the intervention from health care and societal perspectives.
Methods: Twelve-month randomized controlled trial. A total of 216 primary care patients meeting the American College of Rheumatology criteria for FM participated in the study. The intervention included 9, 2-hour sessions of psychoeducation (5 sessions of education about the illness + 4 sessions of autogenic relaxation) added to usual care provided by a multidisciplinary group in general practice was compared to usual care in the public health system.
Results: At 12-month follow-up, patients who received psychoeducation showed greater improvement in global functional status (Cohen d = 0.36; À2.49 to 3.81), physical functioning (Cohen d = 0.56; 0.08 to 1.00), days feeling well (Cohen d = 0.40; À 0.16 to 1.02), pain (Cohen d = 0.35; À 0.04 to 0.80), morning fatigue (Cohen d = 0.24; À0.20 to 0.76), stiffness (Cohen d = 0.34; À0.10 to 0.87), and depression (Cohen d = 0.30; À0.26 to 0.93). Mean incremental cost per person receiving the intervention was hÀ 215.49 (À615.13 to 287.81) from the health care perspective, and hÀ 197.32 (À 785.12 to 395.74) from the societal perspective. The incremental gain in qualityadjusted life-years per person was 0.12 (0.06 to 0.19), yielding a "dominant" intervention from both perspectives. The sensitivity analysis suggested that the intervention was cost-effective even imputing all missing data.
Discussion: Our findings demonstrate the long-term clinical effectiveness of a psychoeducational treatment program for FM implemented at primary care level and the cost-utility from a health care and societal perspective.
Trial Registration: NCT00550966
Key Words: fibromyalgia, cost-utility, psychoeducational treatment, randomized controlled trial (Clin J Pain 2013;29:702-711) F ibromyalgia (FM) is a debilitating syndrome characterized by chronic widespread pain, disturbed sleep, and fatigue whose pathogenesis is currently unknown. The American College of Rheumatology (ACR) 1 established 2 major diagnostic criteria for classifying FM in adults: a history of widespread musculoskeletal pain for at least 3 months, and patient report of tenderness in at least 11 of 18 defined tender points when digitally palpated with 4 kg per unit area of force. Previous studies carried out in the United States and Europe reported that FM prevalence rates in the general population vary from 0.5% to 5%. 2, 3 The ratio of women to men with FM varies between 9:1 and 20:1, and it is usually diagnosed between the ages of 20 and 50 years. 4 The syndrome affects approximately 2% to 6% of adult patients seen by general practitioners 4 and 10% to 20% of those consulting rheumatologists. 5 Several studies have confirmed the high economic burden of FM in industrialized countries. A study conducted in the United States 6 indicated that annual costs in 1998 related to health care utilization, medication, and work loss were $5163 for people with FM and $2486 in the overall employee sample. A more recent work that focused only on direct costs 7 found that FM patients were more likely than patients in the age-matched and sex-matched comparison group to have received pain-related medications, non-painrelated medications, and any combination of pain-related medications. Moreover, the mean number of appointments with the physician was 4 times higher among FM patients over 12 months. Mean total direct costs were about 3 times higher among FM patients than in patients in the comparison group ($9573 vs. $3291). A Dutch study 8 found that patients with FM referred to a specialist have a different pattern of health care consumption, more productivity loss, and higher average annual disease-related total societal costs (h7813) than patients with ankylosing spondylitis (h3205).
Recent meta-analyses have provided evidence about the short-term and long-term effectiveness of some nonpharmacological treatments for FM. [9] [10] [11] [12] However, there is currently a lack of empirical evidence regarding the costeffectiveness or cost-utility of these types of interventions. 13 In fact, only 3 studies have analyzed the cost-utility of nonpharmacological interventions for FM. [14] [15] [16] Bearing in mind that costs are of crucial importance for decision makers, who usually consider as first-choice treatment those interventions with the lowest cost per quality-adjusted life-year (QALY), further empirical evidence of the cost-effectiveness and cost-utility of nonpharmacological interventions is needed. It is important for decision makers that all costs (direct and indirect) are included in economic evaluations. Analyses from the health care perspective include direct costs, that is, costs because of medical resource utilization (medications, medical tests, consultations with health care providers, hospital stays, etc.), whereas analyses from the societal perspective include direct and indirect costs, being the last attributable to production losses (eg, number of days on sick leave).
The objective of the present study was 2-fold: first, to assess the effectiveness at 12-month follow-up of adding a psychoeducational treatment program implemented in primary care to the usual care of public health service for patients with FM. Second, the cost-utility of the intervention was analyzed from both the health care and societal perspectives given the high consequences to society of FM, as reported above.
MATERIALS AND METHODS

Design
This was a controlled trial with a random allocation of participants to 2 groups: usual care + psychoeducational program versus usual care. A detailed description of the study protocol can be consulted elsewhere. 17, 18 The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its subsequent updates. A local Ethics Committee Board evaluated and approved the study.
Settings and Participants
Three general practices within the metropolitan area of Barcelona (Spain) participated in the study. The general practitioners (GPs) at these centers referred those patients suspected of having FM to the hospital. A rheumatologist from that hospital confirmed or ruled out the diagnosis of FM using the ACR criteria, and included the patients in a database if she/he received a FM diagnosis. In the present study, the sample pool consisted of all patients included in this database between 2005 and 2008. All patients aged 18 to 75 years and contactable by telephone were candidates for inclusion in the study. Exclusion criteria: diagnosis of FM not based on the ACR criteria, cognitive impairment, presence of physical/psychiatric limitations (any severe medical illness, psychotic symptoms or disorders, or substance abuse) that impeded participation in the study assessments, life expectancy <12 months, and absence of schooling.
Procedure
The potential participants were screened through an initial phone interview and were provided a general overview of the study. The research assistant then made an appointment for those patients that agreed to participate in the study. Finally, the research assistant, who was not involved with the treatment and was blind to group allocation, performed all the face-to-face interviews once written consent had been obtained. Data were collected at baseline, upon completion of the intervention, and at 6-and 12-month intervals after baseline evaluation. The educative part of the program (5 sessions) included information about typical symptoms, usual course, comorbid medical conditions, potential causes of the illness, the influence of psychosocial factors on pain, current pharmacological and nonpharmacological treatments, the benefits of regular exercise, and the typical barriers to behavior change. The speakers included 4 GPs and 1 rheumatologist. Participants were encouraged to be active, to ask questions, and to discuss issues with the speakers or with other participants.
Intervention Group
The autogenic training (4 sessions) was led by a clinical psychologist with the main aim of increasing participants' pain control. Autogenic training is a well-known relaxation technique that comprises some standard exercises in which the person teaches the body to respond to verbal instructions. These instructions tell the body to relax and control breathing, blood pressure, heartbeat, and body temperature. With regular practice, the communication between the mind and the body is improved. Secondary objectives were to create a space where conflictual emotional experiences manifested in the participants' bodies could be elaborated and to facilitate emotive exchange with other patients with the same condition. The link between emotions and bodily reactions was often highlighted in addition to the benefits of distracting attention from fibromyalgic pain. The psychologist emphasized the need to practice the relaxation techniques at home daily. The educational sessions were intercalated with the autogenic training ones until the 9 weeks were completed.
Control Group
Patients in the control group received standard medical attention. In Spain, the treatment provided is mainly pharmacological and adjusted to the symptomatic profile of the fibromyalgic patient. Counseling about aerobic exercise adjusted to patients' physical limitations is usually provided. Usual care is an ideal comparator in the case of FM, for which no specific treatment is considered the gold standard of care.
Chronic Medical Conditions Checklist
Medical conditions were assessed at baseline using a yes-or-no checklist including: arthritis, rheumatism, cervical pain, back pain, bronchitis or emphysema, asthma, diabetes, hypertension, heart arrhythmias, heart attack, stroke, gastric or duodenal ulcer, migraines or other chronic headaches, varicose veins, cancer, eyesight problems, and hearing problems. Respondents were asked whether they had experienced any of the symptom-based conditions in the previous 12 months.
Fibromyalgia Impact Questionnaire (FIQ) 20, 21 The FIQ, a measure of functional status, includes 10 questions. The first question contains 10 items related to the ability to perform physical tasks. Each question is rated on a 4 point (0 to 3) Likert-type scale. In the Spanish version, the physical function item contains 9 subitems rather than the original 10. Items 2 and 3 ask the patient to mark the number of days they felt well and the number of days they were unable to work because of FM symptoms. Items 4 to 10 inclusive are horizontal linear scales marked in 10 increments on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety, and depression. Once the initial scoring has been completed, the resulting scores are subjected to a normalization procedure so that all scores are expressed in similar units. Each item has a maximum possible score of 10, which yields a maximum total score of 80 (excluding job-related items), with higher scores indicating greater impact.
EuroQoL-5D questionnaire (EQ-5D) 22
The EQ-5D is a widely used health-related quality of life instrument with a non-disease-specific classification system composed of parts: part 1 is a self-reported description of health problems according to a 5-dimensional classification (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Patients mark one of 3 levels of severity (1 = no problems, 2 = some/ moderate problems, and 3 =severe/extreme problems) in each dimension. The time frame is the day of responding. Combinations of these categories define a total of 243 different health states. Part 2 records the current patient's health on a Visual Analogue Scale; a vertical 10-cm line on which the best and worst imaginable health states score 100 and 0, respectively. The EQ-5D has already demonstrated to be valid and reliable in the Spanish population. 23 
Client Service Receipt Inventory (CSRI)-Adapted 24
The CSRI variant used in this study was designed to collect retrospective data on medication and service receipt: Medication. A profile of the patient's use of all prescribed medications (analgesics, nonsteroidal anti-inflammatory, short-acting and long-acting opioids, etc.) was requested, including the name of the drug, the prescriber, the dosage level, the total number of days taking the drug, the total dosage consumed, the reasons for changing the drug, and adherence. Service receipt. The main categories were: emergency service (total visits), general medical inpatient hospital admissions (total days); outpatient health care services (total visits to general practitioner, nurse, social worker, psychologist, and other community health care professionals). For each service, the sector of provision (public or private) was requested. Patients were also asked about type and number of diagnostic tests administered. The CSRI was administered in all assessments with varying time frames: the previous 3 months at baseline, the previous 2 months at posttreatment, the previous 4 months at 6-month follow-up, and the previous 6 months at 12-month follow-up. Empirical evidence indicates that data obtained by self-report has equal validity to register-collected data. 25 
Statistical Analyses
We examined baseline differences in sociodemographic and clinical characteristics between the intervention and control group, applying the Student t test for continuous variables and the w 2 test with continuity correction (or 2-sided Fisher exact test when appropriate) for categorical data.
Effectiveness in Functional Status
After normal distributions were assessed using the Kolmogorov-Smirnov test, we used analyses of covariance (ANCOVAs), including baseline values as a covariate, to examine differences between the 2 groups at 12-month follow-up in the FIQ total score and in each of the FIQ domains (physical impairment, days not feeling well, pain, general fatigue, morning fatigue, stiffness, anxiety, and depression). ANCOVA has been shown to have greater power to detect change than analysis of variance (ANOVA) in randomized study designs. 26 The posttreatment and 6-month follow-up data were not analyzed here as we wanted to focus solely on the main assessment period (12-month follow-up). Following the Consolidated Standards Of Reporting Trials guidelines, 27 we performed intention-to-treat analyses that included all participants who underwent random allocation using the conservative approach of last observation carried forward (LOCF) to replace missing values. The overall a-level was set at 0.05. The outcomes are also illustrated by means of effect sizes, reporting the Cohen d for each comparison. The convention for Cohen d is that 0.20 is small, 0.50 is medium, and 0.80 is large.
Descriptions of Costing Procedure
Costs were estimated from the health care and societal perspective during the 1 year of follow-up. Direct health care costs were calculated by adding the costs derived from medication consumption, medical tests, use of healthrelated services, and cost of staff to run the intervention. The cost of medication was calculated by determining the price per milligram during the study, according to the Vademecum International (Red Book; edition 2008), and included value-added tax. Total costs of medications were calculated by multiplying the price per milligram by the daily dose in milligrams and the number of days receiving such treatment. The main source of unit cost data related to medical tests and use of health services was provided by the official tariffs published in the Official Bulletin of the Catalonia Government for 2008. The calculation of total costs per patient of the intervention was based on the invoices provided by the professionals that were not staff of the 3 participating primary care centers as well as on the price per hour of a locum of those professionals who were staff at the centers. To assess the cost per patient of the group psychoeducational program, the number of attended sessions was taken into account.
Indirect costs were calculated considering the days on sick leave and multiplying them by the minimum daily wage in Spain for 2008. Transfer costs (eg, benefit payments for disability or unemployment), included in some cost of illness studies, were excluded from our cost-utility analysis because they represent an accounting cost to the government, but not to the society as a whole. 28 Finally, total costs were calculated by adding direct and indirect costs. The unit costs are expressed in euros based on prices in 2008.
Utilities
Utilities represent the rating of the patients' quality of life on a scale from 0 (as bad as death) to 1 (perfect health). Negative values are possible indicating a health state that is "worse than death." Patients described their quality of life using the EQ-5D, which is preferred for economic evaluations from a societal perspective. QALYs were calculated using Spanish tariffs of EQ-5D.
Cost-Utility Analysis
Cost-utility was explored through the calculation of incremental cost-utility ratios (ICURs), defined as the difference in mean costs divided by difference in mean QALYs. 29 As the duration of the study was 12 months, neither costs nor outcomes were subjected to discounting. QALYs gained in each evaluation were approximated by using the area under-the-curve technique.
To gain insight into the uncertainty around the pooled mean ICUR, we plotted the pooled bootstrapped cost-effect pairs on cost-utility planes. Bootstrapping involves resampling with replacement from the original sample a sufficiently large number of times to approximate the distribution of the population from which the original data were drawn. 30 our analyses, 1000 samples were generated. This distribution is used to calculate the probability that each of the treatments is the optimal choice, subject to a range of possible maximum values (ceiling ratio) that a decision maker might be willing to pay for a unit improvement in outcome. Costutility acceptability curves are presented by plotting these probabilities for a range of possible values of the ceiling ratio. 31 The acceptability curve represents the probability that the intervention is cost-effective, given a varying threshold for the willingness to pay for each QALY gained. The curves obtained incorporate the uncertainty that exists around the estimates of expected costs and expected effects associated with the intervention. 32 We assumed that data were missing completely at random. Only patients with both cost and relevant outcome data at 12-month follow-up were included in the cost-utility analyses. Notwithstanding, the robustness of the cost-utility results was tested by also imputing missing 12-month data (sensitivity analysis). The cost imputations were performed using the multiple imputation procedure in STATA, and missing EQ-5D data at 12-month follow-up were imputed using the LOCF method. Statistical analyses were performed using SPSS 19.0 and STATA 11.0. Figure 1 illustrates the flow of participants through the trial. The response rate was 85.6%, 83.3%, and 81.5% at posttreatment, 6-month, and 12-month follow-up, respectively. Twenty-seven cases (12.5%) were dropouts (dropouts = patients that explicitly chose to discontinue from the study). The dropout rate was 10.2% in the intervention group and 14.8% in the control group. The mean number of psychoeducational sessions attended was 5.9 (SD = 2.9; range, 0 to 9). Table 1 displays the groups' baseline characteristics. There were no statistically significant differences between the 2 arms in any key variable. Table 2 displays descriptive statistics (means and SDs) at baseline and at 12-month follow-up. Given that the intention-to-treat analyses used all 216 participants recruited, FIQ missing values of 40 cases (18.5%) had to be imputed at 12-month follow-up using the LOCF method. The ANCOVAs yielded significant effects on global functional status and in 6 of the 8 FIQ dimensions. At 12-month follow-up, the intervention was more effective than usual care in reducing physical impairment, days not feeling well, pain, morning fatigue, stiffness, and depression. The magnitude of the effect size was small to medium in global functional status, but was not equally distributed among the 6 dimensions because it was medium in 1 dimension (physical impairment), and small in 5 dimensions (days not feeling well, pain, morning fatigue, stiffness, and depression). Table 3 displays the 12-month mean costs by cost category and treatment group. A total of 176 out of 216 patients had both cost and relevant outcome data at 12-month follow-up. Missing data for the costs variables at 2-month and 6-month follow-up periods were imputed using the multiple imputation procedure in STATA software (8 out of 176 patients had missing values in both periods). Cost imputations were based on variables expected to predict follow-up costs at these 2 time periods: randomization group, baseline age, sex, duration of the condition, and other time period cost values. 33 Missing EQ-5D data at 2-month and 6-month follow-up periods were imputed using the LOCF method (10 out of 176 patients had missing values in both the periods).
RESULTS
Participant Flow
Group Baseline Characteristics
Effectiveness in Functional Status (FIQ)
Cost-Utility Analyses
There was no significant difference in direct medical cost or in total costs between the intervention and control group over the 3 months before randomization. The bootstrapped regressions adjusting by baseline values yielded no significant differences between the 2 groups at 12-month follow-up with regard to the mean total direct medical costs [difference = À215.49; 95% confidence interval (CI), À615.13 to 287.81] and total costs (difference = À 197.32; 95% CI, À785.12 to 395.74). There was a significant difference in QALYs between the 2 study conditions at 12-month follow-up (difference = 0.12; 95% CI, 0.06 to 0.19). The ICURs indicated that the intervention (usual care + psychoeducation) was dominant from the health care and societal perspective.
Uncertainty concerning the ICURs as calculated from the models was expressed using cost-utility planes. These planes have a horizontal axis representing the difference in QALYs, and a vertical axis representing the difference in costs dividing the plane into 4 quadrants. Each dot of the cost-utility planes represents a bootstrap replication of the ICUR. Figure 2 shows the degree of uncertainty around the differences in costs and QALYs between the intervention and control group, from the health care and societal perspective.
As can be seen, in both cases most points were situated in the south east quadrant representing QALY gain at reduced cost; the intervention being highly beneficial from the health care and societal perspective. Finally, cost-utility acceptability curves were plotted (Fig. 3) .
Attaching no value to a QALY yielded probabilities of 85% and 74% of the psychoeducation intervention being cost-effective from the health care and societal perspective, respectively. If decision makers were willing to pay h3000 for psychoeducation, there was a 98% and 95% probability that supplementing usual care with psychoeducation was more cost-effective than usual care alone.
Sensitivity Analysis
After complete imputation, there were no differences between the 2 groups at 12-month follow-up with regard to the mean total direct medical costs (difference = À225.28; 95% CI, À 548.69 to 200.89) and total costs (difference = À 188.99; 95% CI, À629.76 to 317.09). There was a smaller QALY advantage for the psychoeducation + usual care compared with usual care alone, although the difference remained statistically significant (difference = 0.10; 95% CI, 0.04 to 0.15). The ICURs indicated that the intervention was dominant from the health care and societal perspective.
DISCUSSION
We found that usual care complemented with a 9-week psychoeducation program (composed of education + autogenic relaxation) is effective for FM within a general practice setting. The new intervention produced a greater increase in global functional status than usual care alone. Specific improvements were reported in physical function, days feeling well, pain, morning fatigue, stiffness, and depression. The present results replicate those obtained at 6-month follow-up 34 where significant between-group differences were observed in the same domains (with the exception of stiffness).
The intervention was effective compared with usual care alone because it incurred less cost and resulted in more QALYs from both the public health care payer and the societal perspective. Moreover, the examination of the acceptability curves permits us to conclude that the new intervention might be considered cost-effective for any European policy maker taking current country-specific investment ceilings into account. The conclusions were not affected by the subsequent sensitivity analysis, in which we imputed all missing cost and outcome data. Some strengths of the study can be highlighted: we used a randomized controlled trial (RCT) design with a long follow-up period in a naturalistic setting; the economic evaluation followed the International Society for Pharmacoeconomics and Outcomes Research core recommendations for cost-effectiveness and cost-utility analyses alongside RCTs 35 ; the clinical findings are reported in accordance with the Consolidated Standards Of Reporting Trials statement. 27 Comprehensive interpretation and reporting of data was performed, providing not only statistical significance tests, but also the magnitude of effects, and the associated uncertainty 36 ; usual care was the only condition that reflects current clinical practice in the context of public health care in Spain, providing a meaningful comparison to determine the added value of the psychoeducational program and potential inclusion in future guidelines.
We also note some study limitations of our study: the reliance of the clinical effectiveness analysis on a single instrument (the FIQ), which does not allow determination of the effects of the new intervention on other relevant health outcomes in FM, such as pain catastrophizing 37 ; the lack of an active control group constitutes another limitation. We cannot rule out that the significant betweengroup differences on functional status could be a function of simply being enrolled in an intervention, the consequence of getting additional contact time with health care providers, or the nonspecific social benefit of belonging to a group for 9 weeks. Additionally, program completion, which could be defined as having attended at least 6 of 9 psychoeducational sessions, was achieved by only 68% of the participants, which represents an adherence problem.
Nevertheless, this modest percentage is not surprising, given that according to Sephton et al 38 it is common to find high dropout rates and poor attendance in FM intervention studies. To address this problem in future FM studies, we find very useful the strategy reported by Wang et al, 39 who maximized adherence by an oral and written commitment from all participants at the baseline evaluation. In addition, they asked participants who missed a class to attend a makeup class; we did not evaluate treatment fidelity. Therefore, we cannot conclusively determine whether the clinicians applied with exactitude the intervention we describe in the present work. At least 2 independent assessors should have recorded and rated sessions for adherence to the treatment protocol; cost-utility analyses are often questioned because they are based a nonprecise methodology that generates uncertainty related to the findings 40, 41 ; direct costs were likely understated because we did not include direct non-health care costs in our study (eg, patient's travel costs or temporary hired caregivers).
Concerning indirect costs, it is noteworthy that we did not assess productivity losses related to reduced efficiency at work and unpaid work (eg, household work), because of the methodological difficulties involved in measuring these losses. We used economic tariffs instead of unit costs because in Spain there are no published unit costs, which may differ slightly from real unit costs; and finally, the findings are obtained in the Catalan health system, which may be different in some respects from other European public health systems. Catalonia was the first autonomous community in Spain to take on health care responsibilities in 1981. In Catalonia, the National Healthcare Service is financed by the general taxes levied by the state. Medical visits and tests as well as hospital admissions are fully covered by the National Healthcare Service. In 2006, a review paper 13 pointed out that economic evaluations were very scarce in the FM literature, a surprising finding given the high economic burden caused by the syndrome. 42 Of the 23 published papers evaluating pharmacological therapy, only 10 had some form of cost measures, whereas of the 48 nonpharmacological trials, only 33 had some form of cost measure. Only 22 of all assessed trials went beyond 3 months, a problematic aspect given that most interventions need several weeks before an initial improvement is observed, and only 6 trials had >100 total participants. Finally, the authors recommended the use of disease-specific instruments rather than general health measures to detect the change produced by the interventions. In our opinion, the economic evaluation reported here bypasses most of the limitations and shortcomings reported by Robinson and Jones because there was a large sample size in each study arm, and the primary outcome measure was collected by means of a diseasespecific instrument (the FIQ). In addition, the follow-up periods (2, 6, and 12 mo) were sufficiently long to capture important costs and outcomes.
Only 3 studies have specifically addressed the costeffectiveness or cost-utility of nonpharmacological treatments for FM, yielding inconclusive results. In a 3-year RCT implemented in a Dutch rehabilitation center outpatient clinic, Goossens et al 14 addressed the issue of whether combined educational-cognitive therapy was costeffective compared with educational therapy alone. The economic evaluation showed that the intervention, combining group education, and group discussion was preferred over the intervention that combined group education and group cognitive therapy as the health care, and non-health care costs were significantly lower in the former. The educational program generated significantly lower costs, but only a small increase in QALYs that was not statistically significant. In another Dutch study, Zijlstra et al 15 addressed the health economic aspects of a spa treatment compared with usual care. Over the 6-month follow-up period, quality of life was higher in the spa group, but over the 12-month follow-up no statistically significant betweengroup differences were found. The ICUR after 6 months of follow-up was h1311/0.04 = h32,775 per QALY gained, and the cost-utility plane was inconclusive as both the upper-right and upper-left quadrants were equally represented within the bootstrapped ratios. A Spanish study 16 assessed the cost-utility of adding an 8-month, supervised, warm-water exercise program to the usual care provided by the public health service. From the health service perspective, each additional QALY gained by the exercise group cost on average h3947. From a societal perspective, the mean cost per QALY was h7878. This study had high methodological quality, but its main shortcoming was that the sample size was small and the sensitivity analyses revealed that certain facilities could influence the cost-utility of the intervention.
When Garcı´a-Campayo et al 43 compared in a metaanalysis the effectiveness of pharmacological and nonpharmacological treatments for FM available in standard primary care settings versus those administered in standard secondary care settings, they did not find significant differences in effect size according to the level of care. The data from our RCT not only lends support to the findings of this meta-analysis but also extend it; demonstrating that a nonpharmacological intervention based on group psychoeducation is cost-effective compared with usual care alone in the context of primary care. The present study reports the first RCT that demonstrates the cost-utility from a health care and societal perspective of a psychoeducational treatment program for FM carried out at primary care level. We consider that interventions similar to FibroQol might be useful not only for FM patients, who improve in self-management of their symptoms, but also for professionals, as they can help to change attitudes towards FM that are currently characterized by high levels of stigma. 44 
